Pfizer starts Phase 2/3 study of oral antiviral drug for adults after COVID-19 exposure
September 28th 2021Pfizer’s study will evaluate the investigational novel oral antiviral candidate PF-07321332 for the prevention of illness in adults living in the same household as someone with COVID-19.
Read More
Autoantibodies in severe COVID-19: Possible culprits in long-term COVID-19 cases
September 24th 2021Stanford University researchers released information indicating that in hospitalized patients with severe COVID-19, the virus can cause production of autoantibodies that can, in effect, cause the body to attack itself and result in inflammatory diseases.
Read More
Upper lid elevation with topical oxymetazoline 0.1%: providing a better view
September 22nd 2021Topical oxymetazoline HCL ophthalmic solution 0.1% (RVL-1201, RVL Pharmaceuticals, Inc.) has the potential to treat patients with varying degrees of severity of acquired ptosis compared with vehicle.
Read More